Fixed-dose oral direct thrombin inhibitor ximelagatran as an alternative for dose-adjusted warfarin in patients with non-valvular atrial fibrillation

被引：0
|
作者：
Olsson, BB
Petersen, P
机构：
[1] Univ Lund Hosp, Dept Cardiol, S-22185 Lund, Sweden
[2] Univ Copenhagen Hosp, Med Ctr, Div Stroke, Hvidovre, Denmark
来源：
EUROPEAN HEART JOURNAL | 2001年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：330 / 330
页数：1
相关论文
共 50 条
  • [41] Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claims
    Lip, Gregory Y. H.
    Noxon, Virginia
    Kang, Amiee
    Luo, Xuemei
    Atreja, Nipun
    Han, Stella
    Cheng, Dong
    Jiang, Jenny
    Abramovitz, Lisa
    Deitelzweig, Steven
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2024, 57 (06) : 1092 - 1102
  • [42] ANALYSIS OF COSTS OF COMPLICATIONS FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS, COMPARING DOSE-ADJUSTED WARFARIN TO LEFT ATRIAL APPENDAGE CLOSURE
    Armstrong, S.
    Amorosi, S.
    Peppa, R.
    Da Deppo, L.
    Garfield, S.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A346 - A346
  • [43] Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation (SPORTIF V)
    [J]. CIRCULATION, 2003, 108 (21)
  • [44] Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
    Garcia Rodriguez, Luis Alberto
    Martin-Perez, Mar
    Vora, Pareen
    Roberts, Luke
    Balabanova, Yanina
    Brobert, Gunnar
    Fatoba, Samuel
    Suzart-Woischnik, Kiliana
    Schaefer, Bernhard
    Ruigomez, Ana
    [J]. BMJ OPEN, 2019, 9 (09):
  • [45] Comparative Effectiveness of Dabigatran versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
    Alonso, Alvaro
    Chen, Lin Y.
    MacLehose, Richard F.
    Lutsey, Pamela L.
    [J]. CIRCULATION, 2013, 128 (22)
  • [46] WARFARIN DISCONTINUATION AND STROKE RISK AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Wang, J.
    Qiao, Y.
    Spivey, C. A.
    Liu, X.
    Phatak, H.
    Mardekian, J.
    Claflin, A. B.
    Kachroo, S.
    Abdulsatter, Y.
    Parker, R. B.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A8 - A9
  • [47] Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
    Breithardt, Guenter
    Baumgartner, Helmut
    Berkowitz, Scott D.
    Hellkamp, Anne S.
    Piccini, Jonathan P.
    Lokhnygina, Yuliya
    Halperin, Jonathan L.
    Singer, Daniel E.
    Hankey, Graeme J.
    Hacke, Werner
    Becker, Richard C.
    Nessel, Christopher C.
    Mahaffey, Kenneth W.
    Califf, Robert M.
    Fox, Keith A. A.
    Patel, Manesh R.
    [J]. HEART, 2016, 102 (13) : 1036 - 1043
  • [48] Persistence Among Patients with Non-Valvular Atrial Fibrillation Beginning Dabigatran or Warfarin
    Francis, Kevin M.
    Siu, Kimberly
    Yu, Chen
    Alvrtsyan, Hasmik
    Rao, Yajing
    Walker, David R.
    Sander, Stephen D.
    Zalesak, Martin
    Miyasato, Gavin
    Sanchez, Herman
    [J]. BLOOD, 2012, 120 (21)
  • [49] The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol
    Sarich, TC
    Johansson, S
    Schützer, KM
    Wall, U
    Kessler, E
    Teng, RL
    Eriksson, UG
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (04): : 388 - 393
  • [50] Predictors of warfarin discontinuation or switching among non-valvular atrial fibrillation patients
    Lip, G. Y. H.
    Keshishian, A.
    Li, X.
    Lee, T. C.
    Mardekian, J.
    Posner, N.
    Luo, X.
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 : 774 - 775
12345